Methotrexate Medac

Methotrexate, the active ingredient in Methotrexate Medac, is an antimetabolite (folate antagonist) presented as a sterile injectable for intraarterial, intramuscular and intravenous use. It is employed to treat various malignant and autoimmune conditions in adult and pediatric patients.

GNH USA supplies Methotrexate Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate Medac acts as a folate antagonist and is indicated for several oncologic and autoimmune disease pathways. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: improves skin lesions and decreases scaling. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant cell proliferation. - Non‑Hodgkin lymphoma: contributes to tumor control as part of combination therapy. - Breast cancer: used in multi‑drug regimens to limit tumor growth.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting. - Fatigue and malaise. - Mucositis (mouth sores). - Alopecia (hair loss). - Elevated liver enzymes. - Mild skin rash.

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia. - Severe infections due to immunosuppression. - Pulmonary toxicity (interstitial pneumonitis). - Hepatotoxicity with fibrosis or cirrhosis. - Renal toxicity, especially with high doses. - Life‑threatening cutaneous reactions such as Stevens‑Johnson syndrome.

Before initiating therapy, clinicians should assess baseline status and monitor patients regularly. - Monitor blood counts: perform complete blood count before each dose. - Assess liver function: check transaminases and bilirubin regularly. - Evaluate renal function: monitor serum creatinine and adjust dose if needed. - Avoid use in active infections: treat infections prior to dosing. - Use effective contraception: methotrexate is teratogenic. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methotrexate interacts with several medicines that may increase toxicity or reduce efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate serum levels. - Penicillins (e.g., ampicillin): may reduce renal clearance. - Sulfonamide antibiotics: additive bone‑marrow suppression. - Live vaccines: risk of severe infection.

Moderate Interactions (Monitor Closely): - Azathioprine: enhanced immunosuppression. - Cyclosporine: increased risk of nephrotoxicity. - Proton‑pump inhibitors: may affect renal elimination. - Warfarin: potential for altered anticoagulant effect.